Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å(Trastuzumab Emtansine) ½ÃÀå : ÀûÀÀÁõº°, ³óµµº°, ¿¬·ÉÃþº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°
Trastuzumab Emtansine Market, By Indication, By Strength, By Age Group, By End User, By Distribution Channel, By Geography
»óǰÄÚµå : 1812461
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,376,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,919,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å(Trastuzumab Emtansine) ½ÃÀåÀº 2025³â¿¡ 25¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 45¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀ̸ç, 2025-2032³â CAGR·Î 8.7%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 25¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 8.70% 2032³â °¡Ä¡ ¿¹Ãø 45¾ï 5,000¸¸ ´Þ·¯

HER2 ¾ç¼º À¯¹æ¾ÏÀ» Ä¡·áÇϱâ À§ÇØ ¼³°èµÈ Çõ½ÅÀûÀÎ Ç×ü¾à¹°Á¢ÇÕü(ADC)¿¡ ÃÊÁ¡À» ¸ÂÃá ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀåÀº ¾Ï Ä¡·áÁ¦ÀÇ Àü¸Á¿¡¼­ Áß¿äÇÑ ºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½ÅÀº Æ®¶ó½ºÅõÁÖ¸¿ÀÇ Ç¥Àû ƯÀ̼º°ú ¿¥Åº½ÅÀÇ ¼¼Æ÷µ¶¼º È¿´ÉÀ» °áÇÕÇÏ¿© Àü½Å µ¶¼ºÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¾Ï¼¼Æ÷¿¡ Á÷Á¢ È­Çпä¹ýÀ» ½ÃÇàÇÏ´Â Á¤¹ÐÀǷḦ ½ÇÇöÇÕ´Ï´Ù. ÀÌ Ä¡·á¹ýÀÇ ¹ßÀüÀº HER2 ¾ç¼º ÀüÀ̼º À¯¹æ¾Ï ȯÀÚ, ƯÈ÷ Æ®¶ó½ºÅõÁÖ¸¿°ú Ź»ê ±â¹Ý Ä¡·á¸¦ ¹ÞÀº ÀûÀÌ Àִ ȯÀÚµéÀÇ Ä¡·á ÆÐ·¯´ÙÀÓ¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù.

ÀÌ ½ÃÀå¿¡´Â Á¦¾à»ç, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ, ±ÔÁ¦ ´ç±¹, ȯÀÚ Áö¿ø ´Üü µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Âü¿©Çϰí ÀÖÀ¸¸ç, ÀÌ ¸ðµç ÀÌÇØ°ü°èÀÚµéÀÌ ÀÌ »ý¸íÀ» ±¸ÇÏ´Â Ä¡·á¹ýÀÇ °³¹ß°ú º¸±Þ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÀÇ·á°¡ ¾Ï ºÐ¾ß¿¡¼­ °è¼Ó ÁÖ¸ñ¹Þ°í ÀÖ´Â °¡¿îµ¥, Æ®¶ó½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀº º¸´Ù Ç¥ÀûÈ­µÈ È¿°úÀûÀÎ Ä¡·áÁ¦·ÎÀÇ ÁøÈ­¸¦ »ó¡ÇÕ´Ï´Ù. ¼¼°è ½ÃÀå ¿ªÇÐÀº À¯¹æ¾Ï ¹ßº´·ü Áõ°¡, HER2 °Ë»ç¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë, º´¿ë¿ä¹ý ¹× ÀûÀÀÁõ È®´ë¸¦ À§ÇÑ ÁøÇà ÁßÀÎ Àӻ󿬱¸ µîÀÇ ¿äÀο¡ ¿µÇâÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¿äÀεéÀº ÀÌ ½ÃÀåÀ» ´õ ³ÐÀº ¾Ï Ä¡·áÁ¦ ºÎ¹®¿¡ Áß¿äÇÑ ±â¿©¸¦ ÇÏ´Â ½ÃÀåÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀåÀº ±¹Á¦ ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡ °ÉÃÄ Áö¼ÓÀûÀ¸·Î È®´ëµÇ°í ÀÖ´Â ¸î °¡Áö °­·ÂÇÑ ÃËÁø¿äÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ±× ù ¹øÂ° ¿äÀÎÀº Àü ¼¼°è À¯¹æ¾Ï ȯÀÚÀÇ ¾à 20-25%°¡ HER2 ¾ç¼º À¯¹æ¾ÏÀ¸·Î Àü ¼¼°è À¯¹æ¾Ï ȯÀÚÀÇ ¾à 20-25%°¡ HER2 ¾ç¼º À¯¹æ¾Ï¿¡ °É¸®°í ÀÖ½À´Ï´Ù. Áø´Ü ´É·ÂÀÇ Çâ»ó°ú HER2 °Ë»ç ÇÁ·ÎÅäÄÝÀÇ º¸±ÞÀ¸·Î ȯÀÚ ½Äº° ¹× Ä¡·á¹ý ¼±ÅÃÀÌ Å©°Ô °³¼±µÇ¾î ½ÃÀå ¼ºÀå¿¡ Á÷Á¢ÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ È­Çпä¹ý ´ëºñ Æ®·ç½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀÇ ¿ì¼öÇÑ È¿´É ÇÁ·ÎÆÄÀÏÀº ¹«ÁøÇà »ýÁ¸À²°ú Àüü »ýÁ¸À² °³¼±À» º¸¿©ÁÖ´Â Áß¿äÇÑ ÀÓ»ó½ÃÇèÀ» ÅëÇØ ÀÔÁõµÇ¾î ÀÇ»çµéÀÇ Ã¤Åðú ȯÀÚµé ¼ö¿ä¸¦ Áö¼ÓÀûÀ¸·Î °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

±×·¯³ª ÀÌ ½ÃÀåÀº ³Î¸® ÀÌ¿ëµÇ°í äÅõǴ °ÍÀ» ¹æÇØÇÏ´Â Å« ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Æ®¶ó½ºÅõÁÖ¸¿ ¿¥ÅĽÅÀÇ Ä¡·áºñ´Â ȯÀÚ 1ÀÎ´ç ¿¬°£ 10¸¸ ´Þ·¯°¡ ³Ñ´Â °í°¡À̸ç, ƯÈ÷ ÀÇ·á ¿¹»êÀÌ ÇÑÁ¤µÈ ½ÅÈï ±¹°¡¿¡¼­´Â ÀÇ·á ½Ã½ºÅÛ, º¸Çè ÇÁ·Î¹ÙÀÌ´õ, ȯÀڵ鿡°Ô Å« °æÁ¦Àû À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ±î´Ù·Î¿î ½ÂÀÎ °úÁ¤°ú º¹ÀâÇÑ Á¦Á¶ ¿ä°ÇÀº ½ÃÀå ÁøÀÔ À庮°ú °ø±Þ¸Á¿¡ ´ëÇÑ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç÷¼ÒÆÇ °¨¼Ò, °£µ¶¼º, ½ÉÀå ±â´É Àå¾Ö¿Í °°Àº ÀáÀçÀûÀÎ ºÎÀÛ¿ëÀº ȯÀÚÀÇ ½ÅÁßÇÑ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇϸç, Ä¡·á ÀÚ°ÝÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí ÀüÀ̼º À¯¹æ¾Ï ¿Ü¿¡µµ ¼ö¼ú ÈÄ º¸Á¶¿ä¹ý, À§¾Ï µî HER2 ¾ç¼º ¾Ç¼º Á¾¾ç¿¡ ´ëÇÑ ÀûÀÀÁõÀÌ È®´ëµÇ¸é¼­ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ßÀº ºñ¿ë Àý°¨°ú ½ÃÀå Á¢±Ù¼º È®´ëÀÇ ±âȸ°¡ ÀÖÀ¸¸ç, ¸é¿ª¿ä¹ý ¹× ´Ù¸¥ Ç¥ÀûÄ¡·áÁ¦¿ÍÀÇ º´¿ë¿ä¹ý Àü·«Àº Ä¡·á ¼º°ú Çâ»ó°ú ´Ù¾çÇÑ È¯ÀÚ±º¿¡¼­ ½ÃÀå È®´ë °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, ³óµµº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, ¿¬·ÉÃþº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Trastuzumab Emtansine Market is estimated to be valued at USD 2.54 Bn in 2025 and is expected to reach USD 4.55 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 2.54 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.70% 2032 Value Projection: USD 4.55 Bn

The global trastuzumab emtansine market represents a critical segment within the oncology therapeutics landscape, focusing on an innovative antibody-drug conjugate (ADC) designed to treat HER2-positive breast cancer. Trastuzumab emtansine combines the targeted specificity of trastuzumab with the cytotoxic potency of emtansine, creating a precision medicine approach that delivers chemotherapy directly to cancer cells while minimizing systemic toxicity. This therapeutic advancement has revolutionized treatment paradigms for patients with HER2-positive metastatic breast cancer, particularly those who have previously received trastuzumab and taxane-based therapies.

The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, regulatory bodies, and patient advocacy groups, all contributing to the development and accessibility of this life-saving treatment. As personalized medicine continues to gain prominence in oncology, trastuzumab emtansine exemplifies the evolution toward more targeted, effective therapeutic interventions. The global market dynamics are influenced by factors such as increasing breast cancer incidence rates, growing awareness of HER2 testing, expanding healthcare infrastructure in emerging markets, and ongoing clinical research exploring combination therapies and expanded indications, positioning this market as a significant contributor to the broader oncology pharmaceutical sector.

Market Dynamics

The global trastuzumab emtansine market is propelled by several robust drivers that continue to fuel its expansion across international healthcare systems. The primary driver remains the increasing global incidence of HER2-positive breast cancer, affecting approximately 20-25% of all breast cancer patients worldwide, creating a substantial patient population requiring targeted therapeutic interventions. Enhanced diagnostic capabilities and widespread implementation of HER2 testing protocols have significantly improved patient identification and treatment selection, directly contributing to market growth. The superior efficacy profile of trastuzumab emtansine compared to conventional chemotherapy regimens, demonstrated through pivotal clinical trials showing improved progression-free survival and overall survival rates, continues to drive physician adoption and patient demand.

However, the market faces considerable restraints that challenge widespread accessibility and adoption. The exceptionally high cost of trastuzumab emtansine treatment, often exceeding US$ 100,000 annually per patient, creates significant financial barriers for healthcare systems, insurance providers, and patients, particularly in developing economies with limited healthcare budgets. Stringent regulatory approval processes and complex manufacturing requirements contribute to market entry barriers and supply chain challenges. Additionally, potential adverse effects including thrombocytopenia, hepatotoxicity, and cardiac dysfunction require careful patient monitoring and may limit treatment eligibility. Despite these challenges, substantial opportunities emerge from expanding indications beyond metastatic breast cancer, including adjuvant settings and other HER2-positive malignancies such as gastric cancer. Biosimilar development presents opportunities for cost reduction and increased market access, while combination therapy strategies with immunotherapies and other targeted agents offer potential for enhanced therapeutic outcomes and market expansion in diverse patient populations.

Key features of the study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Trastuzumab Emtansine Market, By Indication, 2020-2032, (USD Bn)

5. Global Trastuzumab Emtansine Market, By Strength, 2020-2032, (USD Bn)

6. Global Trastuzumab Emtansine Market, By Age Group, 2020-2032, (USD Bn)

7. Global Trastuzumab Emtansine Market, By End User, 2020-2032, (USD Bn)

8. Global Trastuzumab Emtansine Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Trastuzumab Emtansine Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â